Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res. 2009;11(2):302. doi: 10.1186/bcr2243. Epub 2009 Apr 24.

Number crunching in the cancer stem cell market.

Author information

1
Centre for Diabetes and Metabolic Medicine, ICMS, Barts and The London School of Medicine and Dentistry, London, UK. m.alison@qmul.ac.uk

Abstract

Like their normal counterparts, many tumours are thought to have a hierarchical organization, albeit a disorganized one. Accordingly, the concept of cancer stem cells has emerged, and that these cells are responsible for perpetuating tumour existence. Operationally, cancer stem cells are regarded as prospectively purified cells that are the most effective at tumour initiation in an in vivo assay, usually after xenotransplantation to NOD/SCID mice. The conventional wisdom is that such tumour-initiating cells are rare based upon having to xenotransplant large numbers of human tumour cells into immunodeficient mice to propagate the tumour, but new evidence indicates that perhaps these cells are not so rare, at least in malignant melanoma, if a supportive soil is provided for the transplanted cells along with further restriction of the murine host's immune response.

PMID:
19439026
PMCID:
PMC2688947
DOI:
10.1186/bcr2243
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center